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Postoperative cognitive dysfunction (POCD) is an increasingly recognized problem. Age and preexist-ing cognitive impairment are predisposing factors,1–3 and 25% to 40% of patients aged 60 years or older have POCD 1 week after noncardiac surgery.2–4 The etiology of POCD is unclear. Several mechanisms have been investi-
gated,5 and although the type of anesthesia does not seem to 
play a role,6,7 the contribution of perioperative medications 
remains largely unknown.
Cerebral cholinergic transmission plays a key role in 
cognitive function. A central cholinergic deficit has been 
demonstrated to be associated with age-related cognitive 
impairment,8 and anticholinergic drugs are associated with 
impaired cognitive functions9–12 and delirium.13–15 Elderly 
people and especially those with altered cognitive func-
tions16 are sensitive to central anticholinergic side effects, 
which may already occur at standard doses of frequently 
prescribed drugs.14,17 More than 600 drugs have some 
anticholinergic activity, and 14 of the 25 most commonly 
prescribed medications for older adults have detectable 
anticholinergic effects.17 During the perioperative phase, 
many substances with anticholinergic effects are adminis-
tered, and disturbed cholinergic transmission is considered 
a possible cause of POCD.18
Serum anticholinergic activity (SAA) can be measured 
as a marker of anticholinergic burden in a patient’s blood 
using a radioreceptor assay.19 Independent of the source 
of the anticholinergic activity, SAA reflects the binding of 
all compounds present in a person’s serum to muscarinic 
receptors.20 Increased SAA has been shown to be associated 
with cognitive impairment or delirium in several studies 
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involving elderly patients taking anticholinergic drugs reg-
ularly,16,21–23 although the precise relationship between SAA 
and cognitive performance is not established. Moreover, 
SAA seems to be a stronger predictor of cognitive decline 
than age.21
To the best of our knowledge, repeated measurements of 
SAA in patients with and without POCD have not been used 
in the perioperative setting to investigate the link between 
anticholinergic activity and POCD. To explore the role of 
anticholinergic medication in the development of POCD, 
we tested the hypothesis that an increase in SAA during the 
perioperative period is associated with the occurrence of 
POCD in elderly patients.
METHODS
Subjects
After obtaining approval by the Regional Ethics Committees 
of Basel and Lausanne and written informed patient con-
sent, 79 patients aged ≥65 years scheduled for elective major 
noncardiac surgery were enrolled in this study. Exclusion 
criteria were neurosurgery, carotid endarterectomy, a his-
tory of cerebrovascular disease, a preoperative Mini-Mental 
State Examination (MMSE) score <24/30, and long-term 
psychiatric medication. The study was registered at www.
clinicaltrials.gov (NCT00512200). Some of the patients also 
participated in a study exploring intraoperative cerebral 
autoregulation and cerebral oxygenation.24
Anesthesia
All patients received standardized general anesthesia 
using thiopental (3–5 mg/kg) for induction, and sevoflu-
rane, fentanyl, and atracurium for maintenance. All other 
aspects of the anesthetic management (dosing of sevoflu-
rane and fentanyl, arterial blood pressure targets, use of 
vasoactive drugs, reversal of the neuromuscular blockade) 
were left to the discretion of the anesthesiologist in charge. 
Postoperative management on the ward including analge-
sia was prescribed by the surgeons and was not affected by 
this protocol.
Neuropsychological Assessment
Cognitive functions were assessed preoperatively (the day 
before the operation) and 7 days postoperatively or at hos-
pital discharge using the validated German and French 
modified versions of the Consortium to Establish a Registry 
for Alzheimer’s Disease-Neuropsychological Assessment 
Battery (CERAD-NAB).25 This battery, which is an 
extended version of the original to constitute the CERAD-
NAB-Plus, consists of 7 subtests that cover the most com-
monly affected areas of cognitive functioning in patients 
with Alzheimer disease. The cognitive domains were 
assessed, and the corresponding variables were semantic 
memory/executive functions (animal fluency, naming of 
as many animals as possible in 60 seconds), confrontation 
naming (Boston Naming Test, naming of 15 drawn items), 
general level of cognitive functions (MMSE), verbal epi-
sodic memory (Word List—Learning, Word List—Intrusion 
Errors, Word List—Delayed Recall (after 5–10 minutes), 
Word List—Savings (%), Word List—Recognition), con-
structional praxis (Figures—Copy), nonverbal episodic 
memory (Figures—Delayed Recall, Figures—Savings), 
psychomotor speed (Trail Making Test, part A [TMT-A]), 
executive functions (Trail Making Test, part B [TMT-B], 
quotient of TMT-B/TMT-A), phonemic fluency (naming of 
as many words as possible beginning with a specific let-
ter). (Appendix 1, Supplemental Digital Content  1, con-
tains a detailed description of the tests and of the cognitive 
domains that were explored, http://links.lww.com/AA/
A943.) Tests were administered by the same 2 research fel-
lows trained under the supervision of a neuropsychologist. 
The resulting 15 variables (at baseline and follow-up) were 
converted into demographically (age, education, and gen-
der) corrected standard scores (z-scores) based on a norma-
tive sample of 1100 cognitively healthy individuals26 and 
subtracted from each other (i.e., z-score at follow-up minus 
z-score at baseline). If the decline was >1 standard score in 
2 or more of the 15 variables, we considered this meaning-
ful and thus diagnosed POCD.
To compare both SAA and cognitive function on a con-
tinuous scale, the CERAD-NAB total score as described by 
Chandler et al.27 was used to quantify global cognitive per-
formance. This total score is obtained by adding CERAD-
NAB subtest scores (excluding MMSE and constructional 
praxis recall; maximal score = 100) and performing a mul-
tiple regression analysis to correct for demographic sta-
tus (gender, age, and education). The Chandler score has 
been shown to have an excellent discriminability between 
patients with mild cognitive impairment and those without 
cognitive deficits28 and to be applicable to the German ver-
sion of the CERAD-NAB after adapting the demographic 
correction to an indigenous normative sample.28
Serum Anticholinergic Activity
The anticholinergic activity assay was performed at the 
Centre for Addiction and Mental Health (CAMH) in 
Toronto, Canada. Blood samples for the determination of 
SAA were drawn preoperatively and 7 days postoperatively 
or at hospital discharge but always at the time of cognitive 
testing. After centrifugation (2000g for 10 minutes), serum 
was taken and stored at −80°C until further analysis. SAA 
was measured using a radioreceptor assay first described by 
Tune and Coyle19 and commonly applied to determine this 
variable since then.21,29,30 The anticholinergic activity assay 
quantifies the specific binding of tritiated quinuclidinyl ben-
zilate ([3H]QNB; Perkin Elmer, Woodbridge, ON, Canada), 
a potent muscarinic antagonist with specific affinity for the 
5 subtypes of muscarinic receptors, to rat striatum musca-
rinic receptors in the presence of serum. Anticholinergic 
substances in the serum sample compete with the radioac-
tively marked QNB for muscarinic receptor binding sites. 
The receptor–[3H]–ligand complexes are then isolated by fil-
tration and counted by scintillation spectrometry (Beckman 
LS 6000 SC; Beckman Coulter, Brea, CA). The result is stan-
dardized by comparing the binding exhibited by the sample 
to that of a standard solution of atropine (Sigma Aldrich, St. 
Louis, MO) used as a reference compound by measuring its 
propensity to displace 3H-QNB at various concentrations. 
It is expressed in atropine equivalents (pmol/mL), that is, 
the amount of atropine that would be needed to achieve 
the same displacement of 3H-QNB from the muscarinic 
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receptors in 1 mL of serum without anticholinergic activ-
ity. The acceptable assay range is 0.5 to 250 pmol/mL.20 
The inter- and intraassay reproducibility has a coefficient 
of variation of 5.3% to 7.5% and 4.0% to 6.8%, respectively.
Sample Size
Assuming 40% of our patients would develop POCD3 and 
based on the standard deviation (SD) of SAA in a large 
group of elderly volunteers of 1.25,21 54 patients (22 with 
and 32 without POCD) would be needed to be able to detect 
a difference of 1 pmol/mL between groups (power 80%, 
type I error 0.05). A 1-pmol/mL change in SAA is a very 
small increase. The estimated peak concentration reached in 
vitro after a single dose of 10 mg nortriptyline is 0.8 pmol/
mL, and that of a single dose of 20 mg citalopram is 1.2 
pmol/mL.20
To compensate for loss to follow-up and a possibly 
increased SD in our patient population, we increased our 
sample by one-third to ≥72 patients.
Statistical Analysis
Patients were divided into 2 groups according to the pres-
ence or absence of POCD. Descriptive statistics were cal-
culated for age, educational level, pre- and postoperative 
MMSE scores, pre- and postoperative CERAD-NAB raw 
and total (i.e., demographically corrected) scores, interval 
of cognitive testing, pre- and postoperative SAA values, and 
perioperative change in SAA. Because most of the variables 
were not normally distributed, we chose to express results 
as medians and interquartile ranges (IQRs). After visual 
assessment of the distribution of each variable, parametric 
and nonparametric tests were used as appropriate. Pre- and 
postoperative SAA values were compared between groups 
using a Mann-Whitney U test. Hodges-Lehmann median 
differences and corresponding confidence intervals (CIs) 
were calculated using SSC package in Stata. The method 
used for calculating the CIs is robust both to non-normal-
ity and to unequal variability.31 Additionally, an indepen-
dent-samples t test was used to compare the amplitude of 
perioperative changes in SAA in patients with and without 
POCD. The comparison of pre- and postoperative SAA val-
ues, independent of the occurrence or absence of POCD 
and within the 2 groups, was performed using a Wilcoxon 
signed rank test. Median differences and conservative CIs 
(binomial exact) were calculated for the within-group com-
parison. Spearman’s rank correlation coefficients and the 
corresponding 95% CI (based on the Fishers transforma-
tion) were calculated to check for a bivariate correlation 
between the SAA values and CERAD scores pre- and post-
operatively, respectively. Because this calculation indicated 
a poor correlation, we did not perform a regression analysis. 
Statistical calculations were performed using IBM SPSS v20 
(IBM Corp, Zurich, Switzerland) and Intercooled Stata ver-
sion 13.1 for Macintosh (StataCorp, College Station, TX). P < 
0.05 (2-tailed) was considered significant.
RESULTS
Among the 79 patients initially included, 9 did not complete 
all follow-up tests (11.4% dropped out). Six had no postop-
erative SAA value (sample thawed or lost during transport), 
2 withdrew their consent and either did not have a postop-
erative SAA value or had not performed the postoperative 
cognitive testing, and 1 patient died. Our analysis is based 
on the remaining 70 patients, whose characteristics are 
shown in Table 1.
Of the investigated patients, the 32 (45.7%) who devel-
oped POCD were significantly older (77 vs 70 years, P = 0.01) 
and less educated (P = 0.047) than patients without POCD. 
Raw baseline cognitive performance was significantly dif-
ferent (P = 0.041). No relevant difference was found between 
patients with and without POCD regarding gender, dura-
tion of anesthesia, or demographically corrected baseline 
cognitive function. Postoperative testing of the cognitive 
function was performed after a median of 7 days (IQR = 7, 
8) and was comparable in patients with and without POCD 
(Table 1).
Median pre- and postoperative SAA values and the 
median perioperative change in SAA for all patients, 
Table 1.  Patient Characteristics
All patients POCD No POCD
P value  
(POCD/no POCD)
N 70 32 38
Age (y) 72 (67, 77) 77 (68, 79) 70 (67, 74) 0.01a
Gender: male/female (n [%]) 41/29 (59/41) 20/12 (62/38) 21/17 (55/45) 0.540b
Educational level (y) 12 (11, 14) 12 (9, 13) 12 (11, 14) 0.047a
Duration of anesthesia (min) 258 (198, 316) 258 (202, 331) 251 (188, 311) 0.419a
MMSE preop (points) 28.5 (27, 29) 28 (27, 29) 29 (27, 29) 0.210a
MMSE postop (points) 28 (27, 29) 27.5 (25, 29) 29 (28, 30) 0.004a
CERAD rawd score preop (points) 77.5 (69, 85) 73.5 (62, 84) 80 (72, 86) 0.041c
CERAD rawd score postop (points) 82 (71, 90) 75 (64, 87) 86 (79, 91) 0.001c
CERAD totale score preop (points) 92 (86, 99) 91 (81, 99) 93 (87, 100) 0.379c
CERAD totale score postop (points) 96 (89, 104) 93 (85, 101) 99 (93, 105) 0.007c
Postoperative cognitive testing (d) 7 (7, 8) 7 (6, 9) 7 (7, 8) 0.388a
Numeric data are expressed as medians (interquartile range).
POCD = postoperative cognitive dysfunction; CERAD = Consortium to Establish a Registry for Alzheimer’s Disease; MMSE = Mini-Mental State Examination; 
postop = postoperative; preop = preoperative.
aMann-Whitney U test.
b χ2 test.
cIndependent-samples t test.
dNot demographically corrected.
eDemographically corrected.
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patients with POCD, and patients without POCD are sum-
marized in Table 2. We did not find any significant differ-
ences regarding SAA preoperatively (median difference 0.12 
pmol/mL; 95% CI −0.31, 0.57; P = 0.556) or SAA postopera-
tively (median difference 0.25 pmol/mL; 95% CI −0.26, 0.81; 
P = 0.373) between groups. Regarding changes in SAA in 
patients with POCD and without POCD, a median differ-
ence in SAA of 0.08 pmol/mL (95% CI −0.27, 0.59) and 0.02 
pmol/mL (95% CI −0.29, 0.29), respectively, was found and 
there was no statistically significant difference between the 
2 groups (median difference 0.1 pmol/mL; 95% CI −0.31, 
0.52; P = 0.624). Perioperative changes in SAA (ΔSAA) in 
patients with and without POCD are illustrated in Figure 1.
In the general comparison in all patients, independent of 
the presence or absence of POCD, there was no difference 
between pre- and postoperative SAA (P = 0.73). The median 
change from pre- to postoperative in all patients was 0.02 
pmol/mL (95% CI −0.18, 0.17). Little changes in SAA values 
were found in within-patients comparisons. There were no 
significant differences between the pre- and postoperative 
SAA values within the groups (POCD: P = 0.57; no POCD: 
P = 0.89).
Postoperative cognitive function based on MMSE, 
CERAD raw scores, and CERAD total scores was sig-
nificantly different between the groups. The correlation 
between SAA and CERAD total score pre- and postopera-
tively, respectively, was low with a Spearman rank corre-
lation coefficient preoperatively of 0.03 (95% CI −0.21, 
0.26) and postoperatively of −0.002 (95% CI −0.24, 0.23). 
However, our data showed an association between pre- and 
postoperative SAA values (Spearman rank correlation coef-
ficient 0.58 [95% CI 0.40, 0.72; P < 0.001]). Figure 2 shows the 
CERAD total scores in relation to SAA.
All medications administered during the study are listed 
in the Appendix 2, Supplemental Digital Content 2 (http://
links.lww.com/AA/A944). Table 3 shows that few patients 
received anticholinergic drugs, apart from reversal of neu-
romuscular blockade. Table  4 lists the drugs most com-
monly used by study patients and shows that few drugs 
have anticholinergic activity.
DISCUSSION
We measured SAA preoperatively and 1 week postop-
eratively concomitant with neuropsychological testing to 
investigate the potential association between periopera-
tive anticholinergic burden and the occurrence of POCD in 
elderly patients. No association between SAA and POCD 
could be established in this group of patients, neither when 
a classical binary definition of POCD was used nor when 
cognitive function was expressed using a continuous score. 
Postoperative SAA values were similar in both groups, 
and the 95% CI renders clinically relevant differences 
implausible.
Our data suggest that the assumption that SAA rep-
resents inadequate central anticholinergic activity may 
be challenged. Drugs that do not cross the blood–brain 
barrier will contribute to SAA without exerting a central 
anticholinergic effect and without an impact on cognitive 
performance. However, the fact that several studies have 
positively correlated SAA levels with cognitive impairment 
or delirium supports the SAA assay as a reasonable marker 
for central anticholinergic activity.29 In a small observational 
study, Plaschke et al.32 found 2.5-fold higher anticholinergic 
activity in the cerebrospinal fluid than in blood with a close 
linear correlation between the two and concluded that SAA 
adequately reflects the central anticholinergic activity mea-
sured by cerebrospinal fluid levels. In contrast, SAA will not 
be able to detect a dysfunction of cerebral cholinergic trans-
mission, which may occur through mechanisms other than 
anticholinergic side effects of drugs.
In our group of patients, anticholinergic activity was 
generally low (SAA values between 0.5 and 5 pmol/mL)20 
at both times of measurement and in both groups. Whether 
this was due to a rising awareness of unwanted side effects 
of anticholinergics or rather a particularity of our group of 
patients is unclear. The anesthetics used in our protocol 
are not highly anticholinergic (atracurium and fentanyl), 
or their anticholinergic activity is unknown (sevoflurane 
and thiopental). Furthermore, their kinetics make them 
unlikely to have an impact 7 days postoperatively. Only 
2 patients showed moderate anticholinergic activity (SAA 
values 5–15 pmol/mL),20 one of whom developed POCD. 
There was a great variability of SAA in individual patients 
(Fig.  1). We observed increases and decreases in SAA in 
patients with and without POCD and marked changes 
in SAA between the 2 examinations in some patients. We 
have no robust explanation for the decreasing SAA values 
postoperatively. There was no relationship to cognitive 
functions. Mulsant et al.21 have shown even low SAA to be 
associated with cognitive impairment. Subjects with SAA 
≥2.80 pmol/mL (≥90th percentile in their data) were 13 
times more likely to have an MMSE score ≤24 (≤10th per-
centile in their data).21 However, the occurrence of POCD 
in our patients seems to be secondary to other mecha-
nisms. SAA is a transient value, reflecting and following 
Table 2.  Serum Anticholinergic Activity
All patients POCD No POCD
Median difference 
(95% CI;  
POCD/no POCD)
P value  
(POCD/no POCD)
SAA preop (pmol/mL) 1.13 (0.70, 1.82) 1.14 (0.72, 2.37) 1.13 (0.68, 1.68) 0.12 (−0.31, 0.57) 0.556a
SAA postop (pmol/mL) 1.16 (0.65, 2.39) 1.32 (0.68, 2.59) 0.97 (0.65, 1.83) 0.25 (−0.26, 0.81) 0.373a
Change in SAA periop (pmol/mL) 0.02 (−0.52, 0.51) 0.08 (−0.50, 0.70) −0.02 (−0.53, 0.41) 0.1 (−0.31, 0.52) 0.624b
Increase in SAA periopyes (%) 35 (50) 17 (49) 18 (51) 0.230c
SAA values expressed as medians (interquartile range).
POCD = postoperative cognitive dysfunction; SAA = serum anticholinergic activity; postop = postoperative; preop = preoperative; periop = perioperative.
aMann-Whitney U test.
bIndependent-samples t test.
cχ2 test.
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Figure 1. Perioperative changes in serum anti-
cholinergic activity (ΔSAA) in patients with and 
without postoperative cognitive dysfunction 
(POCD). Most patients have small changes in 
SAA, and patients with and without POCD show 
both perioperative decreases and increases in 
SAA, suggesting that SAA is unlikely to be an 
important factor in the development of POCD in 
the majority of these patients.
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Figure 2. Relationship between serum anti-
cholinergic activity (SAA) and Consortium to 
Establish a Registry for Alzheimer’s Disease 
(CERAD) total score. SAA, CERAD total score: 
demographically corrected summary measure 
of cognitive functions on a continuous scale. 
CERAD total scores are depicted in relation to 
(A) preoperative SAA and (B) postoperative SAA 
and (C) changes in SAA (postoperative and pre-
operative, values >0 denote an increase in SAA) 
in relation to concomitant changes in CERAD 
total scores (postoperative and preoperative, 
values <0 denote a decline in cognitive func-
tion). The graphic repartition shows no linear 
inverse relationship between SAA and CERAD 
total score, suggesting that there is no asso-
ciation between SAA and CERAD total score, 
independent of the presence or absence of 
postoperative cognitive dysfunction (POCD). 
Furthermore, the test of Ho demonstrates a 
high probability that SAA and CERAD total score 
are independent factors. Spearman rank corre-
lation coefficient: preoperative = 0.03, postop-
erative = −0.002.
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Table 3.  Drugs with Anticholinergic Activity (Ranked from High to Low) Used by Participants During the 
Study
Drugs Preoperative Perioperative Postoperative (day 7)
No POCD 
(N [%])
POCD
(N [%])
No POCD 
(N [%])
POCD 
(N [%])
No POCD
(N [%])
POCD
(N [%])
Atropine 0 (0) 0 (0) 1 (2.6) 0 (0) 0 (0) 0 (0)
Robinul/neostigmine NA NA 19 (50) 18 (56.2) NA NA
Flavoxate 0 (0) 0 (0) 0 (0) 0 (0) 4 (10.5) 1 (3.1)
Ipratropium bromide/tiotropium 2 (5.3) 1 (3.1) 1 (2.6) 1 (3.1) 3 (7.9) 5 (15.6)
Mirtazapine 0 (0) 1 (3.1) 0 (0) 0 (0) 0 (0) 1 (3.1)
Quetiapine 0 (0) 1 (3.1) 0 (0) 0 (0) 0 (0) 2 (6.2)
The number of patients (N) and the proportion (%) related to the total of patients in each group (no POCD = 38, POCD = 32) are reported.
NA = not applicable; POCD = postoperative cognitive dysfunction.
Table 4.  Most Commonly Used Medications by Participants (>20%, at One Time or Another [Pre-, Peri-, or 
Postoperative] During the Study) and Their Anticholinergic Activity
Drugs
Anticholinergic 
activity Preoperative Perioperative
Postoperative  
(day 7)
No POCD 
(N [%])
POCD
(N [%])
No POCD 
(N [%])
POCD 
(N [%])
No POCD
(N [%])
POCD
(N [%])
Protocol drugs
  Thiopental Unknown NA NA 38 (100) 32 (100) NA NA
  Atracurium No NA NA 38 (100) 31 (96.9) NA NA
  Fentanyl Minimal NA NA 38 (100) 32 (100) NA NA
  Sevoflurane Unknown NA NA 38 (100) 32 (100) NA NA
Neuromuscular  
blockade reversal
  Robinul/neostigmine High NA NA 19 (50) 18 (56.2) NA NA
Analgesics and  
antiinflammatory drugs
  Paracetamol No 2 (5.3) 5 (15.6) 38 (100) 32 (100) 32 (84.2) 24 (75)
  Metamizole Unknown 1 (2.6) 2 (6.2) 34 (89.5) 26 (81.2) 10 (26) 5 (15.6)
  Morphine No 0 (0) 0 (0) 10 (26.3) 8 (25) 1 (2.6) 1 (3.1)
  Methadone Unknown 0 (0) 0 (0) 24 (63.2) 21 (65.6) 0 (0) 0 (0)
Anti-infectives
  Cefuroxime/cefazolin/ 
ceftriaxone
Unknown 1 (2.6) 0 (0) 34 (89.5) 23 (71.9) 1 (2.6) 1 (3.1)
Nervous system
  Benzodiazepines (lorazepam, 
bromazepam, midazolam,  
diazepam)
No/minimal 3 (7.9) 5 (15.6) 28 (73.7) 26 (81.2) 4 (10.5) 5 (15.6)
Cardiovascular system/blood
  Antihypertensive drugs
   β-Blockers No 5 (13.2) 7 (21.9) 7 (18.4) 7 (21.9) 5 (13.2) 7 (21.9)
   “Sartans” No 6 (15.8) 8 (25) 1 (2.6) 2 (6.2) 6 (15.8) 8 (25)
  Vasopressors
   Ephedrine No 0 (0) 0 (0) 24 (63.2) 30 (93.7) 0 (0) 0 (0)
   Phenylephrine No 0 (0) 0 (0) 19 (50) 18 (56.2) 0 (0) 0 (0)
   Norepinephrine No 0 (0) 0 (0) 10 (26.3) 5 (15.6) 0 (0) 0 (0)
  Diuretics
   Furosemide/torasemide Minimal 4 (10.5) 4 (12.5) 2 (5.3) 4 (12.5) 8 (21.1) 6 (18.7)
  Hydrochlorothiazide/ 
chlorthalidone
No 8 (21.1) 8 (25) 1 (2.6) 1 (3.1) 7 (18.4) 7 (21.9)
   Statins No 10 (26) 13 (40.6) 1 (2.6) 1 (3.1) 8 (21.1) 11 (34.4)
   Acetylsalicylic acid No 8 (21.1) 3 (9.4) 3 (7.9) 0 (0) 7 (18.4) 3 (9.4)
   Heparin No 7 (18.4) 5 (15.6) 2 (5.3) 2 (6.2) 11 (28.9) 15 (46.9)
Alimentary tract and metabolism
  Proton pump inhibitors  
(panto-, ome-, and esomeprazole)
No 9 (23.7) 10 (31.2) 6 (15.8) 6 (18.7) 19 (50) 16 (50)
Miscellaneous
  Vitamins and oligoelements (vitamin 
B, calcium, calcium/vitamin D3, 
magnesium, KCl, folic acid, thiamine)
No 10 (26.3) 3 (9.4) 2 (5.3) 2 (6.2) 12 (31.6) 5 (15.6)
Anticholinergic activity: no = 0 pmol/mL; minimal = <0.5 pmol/mL; low = 0.5–5 pmol/mL; moderate = 5–15 pmol/mL; high = >15 pmol/mL. The number of 
patients (N) and the proportion (%) related to the total of patients in each group (no POCD = 38, POCD = 32) are reported.
NA = not applicable; POCD = postoperative cognitive dysfunction.
Adapted from Chew et al.20 and Mintzer and Burns.14
 October 2014 • Volume 119 • Number 4 www.anesthesia-analgesia.org 953
the pharmacokinetic profiles of the drugs and their metab-
olites, which collectively contribute to anticholinergic 
effects. We measured SAA 7 days postoperatively, not 
necessarily at the time of peak concentration. Conversely, 
POCD is a phenomenon that can last weeks to months and 
may even be permanent. It is unknown whether a peak 
of SAA during the first postoperative week could initiate 
POCD, which is diagnosed later after SAA has decreased. 
Our study was not designed to answer this question. 
However, because performing neuropsychological testing 
shortly after surgery seems premature,33 we deliberately 
chose to measure SAA at a time when relevant information 
may be gained from concomitant cognitive testing. Even if 
most studies comparing SAA and cognitive function have 
found a relationship between an increased level of SAA 
and cognitive impairment or delirium,22,29 some investi-
gations have failed to do so.9 Moreover, although the link 
between SAA and cognitive function is well established, it 
does not necessarily imply causality.21 Also, in many stud-
ies, SAA was measured in patients with long-term or regu-
lar exposure to anticholinergic medications or suffering 
from preexisting cognitive impairment.34 This was not the 
case in our subjects, as marked preexisting impairment of 
cognitive functions was an exclusion criterion, and 7 days’ 
exposure to anticholinergic drugs may be insufficient to 
cause cognitive side effects. Furthermore, many other fac-
tors in the perioperative setting could be responsible for 
the development of POCD, for example, the inflammatory 
response1 or the stress response.35,36
The serum anticholinergic assay may have some limita-
tions. Cox et al.37 have suggested that this assay may not be 
an accurate method to quantify SAA because of extensive 
binding of [3H]QNB to plasma proteins. However, from 
their brief description, we believe that there were method-
ological differences. It is not clear whether they allowed the 
samples to equilibrate to reach a balance between plasma 
proteins, muscarinic receptors, and unbound drugs. It is 
also not clear whether they used an atropine standard 
curve in plasma and whether they filtered the plasma for 
the standard curve. The CAMH performed an equilibra-
tion of the samples and used an atropine standard curve 
in plasma. The serum anticholinergic assay is based on the 
amount of [3H]QNB binding to rat brain muscarinic recep-
tors; whether the receptors in human and rodent brains 
react in the same way is unclear. Moreover, nicotinic recep-
tors are also involved in the cholinergic pathway. They 
also modulate cognitive function although they are less 
widely distributed throughout the brain38 and despite the 
fact that the main cognitive effects are mediated by mus-
carinic receptors.12
Determining the incidence of POCD depends on the 
numbers and types of cognitive tests, the manner in which 
they are performed, the definition of how much dysfunc-
tion is clinically relevant, the statistical analysis and criteria 
used for examining change, and the time of postoperative 
assessment.7,39,40 There is no internationally accepted defi-
nition for POCD.40 Most studies evaluating anticholinergic 
effects and cognitive impairment used the MMSE to assess 
the cognitive performance.9 This test is neither designed 
for nor accurate enough to detect POCD. We used the more 
precise and more inclusive CERAD-NAB-Plus test battery, 
which allows the detection of slight changes in cognitive 
function characteristic of POCD, perhaps explaining our 
high percentage of patients with POCD compared to some 
other trials.4 A further explanation for the rather frequent 
incidence of POCD (45.7%) could be the high median age 
of our patients (72 years), which is similar to that of a 
group of patients investigated by Monk et al.3 (incidence 
of POCD 41%, mean age 70 years) but in contrast to the 
results of the ISPOCD1 study (incidence of POCD 26%, 
median age 68 years).4 There is no consensus regarding 
the intervals between surgery and postoperative cognitive 
testing, which is usually chosen for practicality (time of 
discharge, follow-up visit). Similar to ours, many proto-
cols perform the first postoperative test 7 days postopera-
tively. This may be criticized and considered early because 
of the influence of postoperative pain, opioids, or sleep 
disturbance on cognition. On the other hand, delayed test-
ing increases the risk of overlooking short-term POCD.41 
The lack of a matched control group is a weakness of our 
study. However, we have a control group of 60 Swiss vol-
unteers who underwent retesting on day 7 (and 90).42 The 
demographic variables and cognitive function at baseline 
of these volunteers are different from those of our patients 
(better cognitive function in volunteers). For this reason, 
we decided to use the methodologically weaker approach 
of a change from baseline using a demographically cor-
rected baseline based on a large group of volunteers rather 
than a pure baseline. This approach may have led to an 
underestimation of the number of patients with POCD. 
Similar to many other authors, we based our definition of 
POCD on z-scores. This widely used method determines 
a certain predefined grade of decline in the cognitive tests 
but in a binary fashion without considering the severity 
of the cognitive deterioration. Because SAA is a continu-
ous variable, we used the CERAD total score in addition 
to a standard definition of POCD to attempt to describe 
a potential relationship between SAA and cognitive func-
tions and found no association. Defining POCD based on 
a continuous scale such as the CERAD-NAB total score as 
an outcome variable and considering the practice effect 
resulting from the repetition of the neuropsychological 
testing as described by Burkhart et al.42 could be interest-
ing and would be preferable. However, in our opinion, we 
currently do not have enough data to define POCD based 
on the CERAD.
CONCLUSIONS
In this group of patients, with low baseline SAA and low 
anticholinergic burden perioperatively, we were unable 
to demonstrate an association between POCD and SAA. 
While a relationship between anticholinergic drug effects 
and POCD cannot be excluded in some patients, our data 
suggest that POCD may not be a consequence of anticho-
linergic medications administered perioperatively but 
rather due to other mechanisms. Particularly, our meth-
ods do not allow for drawing conclusions on the role of an 
altered central cholinergic transmission because of factors 
such as changes in transmitter synthesis or apoptosis of 
cholinergic neurons. E
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